Medicare Enrolled
Dr. Samuel Aly, M.D.
Urology Physician · Shrewsbury, NJ
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Mixed engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Aly from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Aly?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Aly
Dr. Samuel Aly is an urology physician in Shrewsbury, NJ, with 11 years of NPI registration. Based on federal Medicare data, Dr. Aly performed 6,149 Medicare services across 3,414 unique beneficiaries.
Between the years covered by Open Payments, Dr. Aly received a total of $22,563 from 42 pharmaceutical and/or device companies across 238 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Aly is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 11 years in practice
▲ Top 22% volume in NJ
$22,563 industry payments
Medicare Practice Summary
Medicare Utilization ↗6,149
Medicare services
Top 22% in NJ for urology physician
3,414
Unique beneficiaries
$53
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~559 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Infectious disease DNA/RNA test A laboratory test that uses a specific technique to detect the genetic material of an organism. This method amplifies the target DNA or RNA to identify the presence of the organism. |
1,300 | $34 | $116 |
| Automated urinalysis An automated laboratory test performed on a urine sample to analyze its chemical and physical properties. The procedure uses machinery to detect various substances and cells within the urine. |
776 | $2 | $16 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
550 | $69 | $501 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
472 | $99 | $710 |
| Yeast/candida DNA test A laboratory test that uses an amplified probe technique to detect the presence of Candida species, a type of yeast, in a patient sample. |
300 | $34 | $116 |
| Nucleic acid test for multiple organisms A laboratory test that uses amplified probe techniques to detect the genetic material of multiple organisms in a sample. |
300 | $69 | $233 |
| Ceftriaxone antibiotic injection This code represents the administration of ceftriaxone sodium, an antibiotic medication. The charge is calculated for every 250 mg of the drug administered. |
236 | $0 | $5 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
196 | $12 | $79 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
166 | $65 | $382 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
163 | $140 | $1,064 |
| Cystourethroscopy A diagnostic exam of the bladder and urethra using an endoscope to visually inspect the urinary tract. |
151 | $201 | $1,343 |
| Bladder ultrasound after voiding An ultrasound scan performed after urination to measure the amount of urine remaining in the bladder. |
106 | $8 | $60 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
102 | $120 | $915 |
| CMV nucleic acid detection test A laboratory test that uses amplified probe techniques to detect cytomegalovirus (CMV) genetic material in a sample. |
100 | $34 | $116 |
| VRE nucleic acid detection test A laboratory test that uses amplified probe techniques to detect vancomycin-resistant Enterococcus (VRE) DNA in a patient sample. |
100 | $34 | $116 |
| Herpes simplex virus nucleic acid test A laboratory test that uses an amplified probe technique to detect the genetic material of the herpes simplex virus. |
100 | $34 | $116 |
| Herpes virus-6 nucleic acid test A laboratory test that uses amplified probe techniques to detect the genetic material of herpes virus-6. |
100 | $34 | $116 |
| Staphylococcus aureus DNA test A laboratory test that uses DNA amplification to detect the presence of Staphylococcus aureus bacteria in a sample. |
100 | $34 | $116 |
| MRSA nucleic acid detection test A laboratory test that uses amplified probe techniques to detect the genetic material of methicillin-resistant Staphylococcus aureus (MRSA) bacteria. |
100 | $34 | $116 |
| Strep A nucleic acid amplification test A laboratory test that uses nucleic acid amplification to detect the presence of Group A Streptococcus bacteria. This method identifies the genetic material of the bacteria to determine if an infection is present. |
100 | $34 | $116 |
| Group B Strep DNA test A laboratory test that uses DNA amplification to detect the presence of Group B Streptococcus bacteria. |
100 | $34 | $116 |
| Simple insertion of temporary bladder tube A procedure to place a temporary tube into the bladder. This allows for the drainage of urine from the bladder. |
90 | $47 | $362 |
| Imaging of urinary tract with contrast An imaging test of the urinary tract performed after a contrast agent is injected to enhance visibility of the structures. |
70 | $20 | $423 |
| Ureteral stone crushing with stent insertion An endoscope is used to break up a stone in the ureter, followed by the placement of a stent to keep the ureter open. |
59 | $334 | $2,223 |
| Endoscopic removal of foreign body, stone, or stent from urethra or bladder A procedure to remove a foreign object, stone, or stent from the urethra or bladder using an endoscope. The endoscope is a thin tube with a camera inserted into the urinary tract to locate and extract the item. |
40 | $274 | $1,768 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
37 | $149 | $988 |
| Complete ultrasound of retroperitoneum An ultrasound examination of the structures located behind the abdominal cavity. |
33 | $67 | $625 |
| Electronic assessment of bladder emptying A test that uses electronic monitoring to evaluate how well the bladder empties urine. |
31 | $10 | $78 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
31 | $75 | $616 |
| Radiologist review of ureter or urethra image A radiologist reviews images of the ureter or urethra to evaluate the structures. |
28 | $33 | $679 |
| Transrectal ultrasound of the pelvis An ultrasound imaging procedure where a probe is inserted into the rectum to visualize pelvic structures. |
22 | $82 | $799 |
| Other procedure on male genital system A surgical or medical intervention performed on the male genital organs that does not fall under other specific categories. |
21 | $67 | $1,500 |
| Prostate gland biopsy A procedure to remove small samples of tissue from the prostate gland for laboratory examination. |
20 | $185 | $1,409 |
| Ultrasound guidance for needle placement Use of ultrasound imaging to guide the precise placement of a needle during a medical procedure. |
20 | $38 | $323 |
| Ureteral stent insertion via endoscope A flexible tube is inserted into the ureter using an endoscope to keep the passage open and allow urine to flow from the kidney to the bladder. |
18 | $100 | $2,545 |
| Ureteral stone crushing with endoscope A procedure to break up a stone in the ureter using an endoscope. The endoscope is inserted to locate and crush the stone. |
11 | $96 | $2,094 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.9% high complexity
11.4% medium
86.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$22,563
Total received (2020-2024)
Avg $4,513/year across 5 years
Top 8% in NJ for urology physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
42
Companies
238
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$8,855 (39.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$8,116 (36.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,592 (24.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$9,797
2023
$3,037
2022
$7,471
2021
$1,701
2020
$557
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
INTUITIVE SURGICAL, INC.
$8,450
COLOPLAST CORP
$289
Davol Inc.
$160
PROCEPT BioRobotics Corporation
$150
Ferring Pharmaceuticals Inc.
$82
Dendreon Pharmaceuticals LLC
$81
Antares Pharma, Inc.
$78
ABBVIE INC.
$67
Sumitomo Pharma America, Inc.
$66
PFIZER INC.
$65
Boston Scientific Corporation
$64
Baxter Healthcare
$58
Tolmar, Inc.
$35
Integra LifeSciences Corporation
$26
180 Medical, Inc.
$23
Merck Sharp & Dohme LLC
$20
Calyxo, Inc.
$19
Endo Pharmaceuticals Inc.
$17
Endo USA, Inc.
$17
Olympus America Inc.
$16
Laborie Medical Technologies Corp.
$15
Top 3 companies account for 90.8% of 2024 payments
All-time payments by company (2020-2024) ›
INTUITIVE SURGICAL, INC.
$8,450
BOSTON SCIENTIFIC CORPORATION
$6,807
Boston Scientific Corporation
$2,887
Dendreon Pharmaceuticals LLC
$409
Astellas Pharma US Inc
$364
Davol Inc.
$347
Medtronic, Inc.
$294
COLOPLAST CORP
$289
PFIZER INC.
$268
Sumitomo Pharma America, Inc.
$205
Antares Pharma, Inc.
$192
PROCEPT BioRobotics Corporation
$150
Coloplast Corp
$140
ABBVIE INC.
$138
180 Medical, Inc.
$134
Endo Pharmaceuticals Inc.
$122
Tolmar, Inc.
$109
Janssen Biotech, Inc.
$106
Integra LifeSciences Corporation
$104
Myovant Sciences Inc.
$98
UroGen Pharma, Inc.
$91
UROVANT SCIENCES INC
$85
Ferring Pharmaceuticals Inc.
$82
Intuitive Surgical, Inc.
$81
Merck Sharp & Dohme LLC
$72
DENTSPLY IH AB
$66
Baxter Healthcare
$58
Allergan, Inc.
$54
Myriad Genetic Laboratories, Inc.
$47
Olympus America Inc.
$44
AbbVie Inc.
$43
Supernus Pharmaceuticals, Inc.
$37
Axonics, Inc.
$35
UROGEN PHARMA, INC.
$32
Calyxo, Inc.
$19
Bayer Healthcare Pharmaceuticals Inc.
$18
Endo USA, Inc.
$17
Laborie Medical Technologies Corp.
$15
Merck Sharp & Dohme Corporation
$14
Acerus Pharmaceuticals Corporation
$14
Sun Pharmaceutical Industries Inc.
$14
Hollister Incorporated
$12
Top 3 companies account for 80.4% of all-time payments
Associated products mentioned in payments ›
ADSTILADRIN · ADVANCE · ADVANTAGE · AMS · AMS 700 CXR RTE KIT · AMS 700 CXR RTE Kit · AQUABEAM SYSTEM · ARISTA AH FlexiTip · Axonics · BOTOX · Bovie · CVAC ASPIRATION SYSTEM · Clear Renal Sheath · Da Vinci Surgical System · ELIGARD · ERLEADA · FLEXIVA · GEMTESA · GENERAL ERECTILE DYSFUNCTION · GENERAL - ERECTILE DYSFUNCTION · INTERSTIM · Integra · JELMYTO · KEYTRUDA · LITHOVUE · LUPRON DEPOT · LithoVue · LoFric · MYRBETRIQ · Myrbetriq · NOCDURNA · Natesto · Nubeqa · ORGOVYX · PERCLOT · PROLARIS · PROVENGE · Phasix Mesh · REZUM · SpeediCath · Titan · Urgent PC Neuromodulation System · VaPro · XIAFLEX · XTANDI · XYOSTED · Xtandi · YONSA · iTIND System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (39%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in urology physician and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 8% for urology physician in NJ.
Geographic Context
Urology physicians within 10 mi
150
Per 100K population
23.3
County median income
$122,727
Nearest hospital
RIVERVIEW MEDICAL CENTER
2.6 mi
2.6 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Aly is a clinical cardiology specialist, with above-average Medicare volume (top 22% in NJ), with mixed engagement industry engagement in the top 8% of NJ peers.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Aly experienced with infectious disease dna/rna test?
Based on Medicare claims data, Dr. Aly performed 1,300 infectious disease dna/rna test services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Aly receive payments from pharmaceutical companies?
Yes. Dr. Aly received a total of $22,563 from 42 companies across 238 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Aly's costs compare to other urology physicians in Shrewsbury?
Dr. Aly's average Medicare payment per service is $53. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Aly) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Urology Physicians in Shrewsbury
Browse urology physicians in Shrewsbury ranked by procedure volume and transparency data.
Highest volume
Top Urology Physicians in NJ
Urology physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Urology Physicians in NJ
Which NJ urology physicians receive the most from drug and device companies.
By company
INTUITIVE SURGICAL, INC. Payments to Doctors
See all physicians who received payments from INTUITIVE SURGICAL, INC.
By company
BOSTON SCIENTIFIC CORPORATION Payments to Doctors
See all physicians who received payments from BOSTON SCIENTIFIC CORPORATION.
By company
Boston Scientific Corporation Payments to Doctors
See all physicians who received payments from Boston Scientific Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology